Company History

Company history

Product history

1920

1923

Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.

image of history

icon

1931

Kyorin Chemical Laboratory was established.

icon

1940

The company was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.

icon

1947

The Okaya Plant was started

image of history

icon

1950

1957

The medical journal bulletin “Doctor Salon” was started.

icon

1961

Behyd, a diuretic and antihypertensive agent, was launched.

image of history

icon

1962

Kyorin Chemical Laboratory (later Technical Center of Development) was established.

image of history

icon

1965

The Head Office was completed in Kanda Surugadai.

image of history

1965

KYORIN AP-2, an analgesic, was launched.

Deamelin-S, an oral hypoglycemic agent, was launched.

image of history

icon

1967

The nogi Plant was started.

icon

1971

Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.

icon

1974

Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.

icon

1976

Hydroxyethylstarch (HES) was licensed to Pfrimmer (Germany, present Baxter Deutschland).

icon

1977

Central Research Laboratories were established.

image of history

icon

1980

Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).

icon

1980

1981

Mucodyne, a mucoregulant, was launched.

image of history

icon

1982

Norfloxacin (NFLX) was licensed to Astra (Sweden, present AstraZeneca) and Boots (U.K., present Abbvie).

icon

1983

Norfloxacin (NFLX) was licensed to American Home Products (U.S.A., present Pfizer).

icon

1984

Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.

image of history

icon

1986

Fleroxacin (FLRX), an antibacterial agent, was licensed to F. Hoffmann-La Roche (Switzerland).

1986

APLACE, an agent for gastritis & gastric ulcer, was launched.

icon

1989

Ketas, for bronchial asthma and cerebrovascular disorders, was launched.

Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.

image of history

icon

1991

BACCIDAL Tablet for Children was launched.

icon

1992

KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.

icon

1993

Megalocin (FLRX), a long-acting new quinolone agent, was launched.

icon

1995

Research Center (now Development Research Laboratories) was founded by integrating Research Center of Organic Syntheses,

Technical Center of Development, Technical Center of Product Formulation and Technical Center of Safety Assessment.
The Noshiro Plant was started.

image of history

icon

1996

A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).

1996

Pentasa Tablet, a treatment for ulcerative colitis and Crohn’s disease, was launched.

icon

1998

Milton, an effervescent disinfectant business, was acquired from P&G.

icon

1999

Listed on the Tokyo Stock Exchange, Second Section.

icon

2000

Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin-eyedrops was licensed to Allergan (U.S.A.).

icon

2000

2001

A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.

2001

Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.

image of history

icon

2002

A subsidiary company, Kyorin Europe GmbH (Germany), was established.

2002

Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.

image of history

icon

2004

ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.

icon

2006

The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
The new Noshiro Plant began operating.

icon

2007

A business transfer agreement was made with the Fresenius Kabi AG Group in Germany concerning Hespander and Salinhes, plasma substitutes and hemodilution agents.

2007

Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.

Kipres Fine Granules 4mg, a bronchial asthma treatment drug, was launched.

image of history

icon

2008

KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.

2008

Pentasa Tablet 500, a treatment for ulcerative colitis and Crohn’s disease, was launched.

icon

2009

Marketing rights in China were granted to Senju Pharmaceutical for Gatifloxacin Ophthalmic Solution.
A license agreement for Neramexane, a tinnitus drug, was made with Merz Pharmaceuticals (Germany) for the Japan region.

icon

2010

Mucodyne DS 50%, a mucoregulant, was launched.

icon

2010

2011

Uritos Orally Disintegrating (OD) Tablets 0.1mg, an overactive bladder drug, was launched

icon

2012

Transfer of business related to a topical antifungal prescription drug Pekiron cream 0.5% to Galderma S.A. (Switzerland)

2012

RUBYSTA, a multi-purpose disinfectant cleaner, was launched.

icon

2013

Head office moved to Ochanomizu sola city in Kanda Surugadai.

2013

Pentasa Suppositories 1g, a treatment for ulcerative colitis, was launched.

Flutiform, a combination drug for asthma treatment, was launched.

image of history

icon

2014

Signed a license agreement concerning Vibegron, a therapeutic agent for overactive bladder, with Merck & Co. (U.S.A.).

icon

2015

Established the WATARASE Research Center.

FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)

image of history

2015

Eklira Genuair, a treatment for COPD, was launched.

Pentasa Granules 94%, a treatment for ulcerative colitis and Crohn’s disease, was launched.

image of history

icon

2016

DESALEX Tablets 5mg a treatment of allergic diseases drug was launched

image of history

icon